Dyadic Provides Update On Business Progress And Announces It Will Attend The Bioprocess International Conference In Boston, September 23-26, 2024
Portfolio Pulse from Benzinga Newsdesk
Dyadic International, Inc. (NASDAQ:DYAI) updates on its business progress and announces its participation in the Bioprocess International Conference in Boston in 2024. The company is advancing its C1 and Dapibus™ platforms for efficient protein manufacturing, targeting the alternative protein market and human and animal health sectors. Dyadic is also progressing in partnerships, notably with Proliant Health and Biologicals, and expects revenue growth from recombinant albumin sales.
September 23, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dyadic International is advancing its C1 and Dapibus™ platforms for protein manufacturing, targeting growth in alternative proteins and health markets. The company is strengthening partnerships, notably with Proliant Health and Biologicals, and anticipates revenue growth from recombinant albumin sales.
Dyadic's focus on advancing its platforms and partnerships, particularly with Proliant Health and Biologicals, positions it for growth in the alternative protein and health markets. The expected revenue from recombinant albumin sales and ongoing developments in other protein products suggest a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100